CellCoTec’s management has a proven track record in the discovery, development and commercialization of medical technology products.

Lawrence Kinet - Chief Executive Officer and Executive Director

has been in leadership positions in the medical device industry for more then 30 years. He has successfully managed both large and small companies. He has completed more than a billion dollars of acquisitions. He has taken a company through an IPO and has chaired and served on the board of several start-up medical device businesses. He has built, integrated and managed sales forces in the U.S. and Europe. His medical device career started at Baxter International where he rose to be the President of the International Division. He then spent 12 twelve years in the world of early stage and development companies. He co-founded the Kensington Group, which acted as interim CEO for early stage medical device and biotechnology companies. He led a bio-pharmaceutical company to and through clinical trials and took an early stage medical device company onto NASDAQ. He has raised more than $120 million for a number of early stage medical device companies. Most recently, he was the CEO of Smiths Medical, a core business of Smiths Group PLC. He was a Main Board Director of Smiths Group. During his time at Smiths, he transformed the medical device business from a series of stand-alone companies into one integrated medical device business. He completed acquisitions valued at more than a billion dollars during his time at Smiths, including Medex. Smiths Medical generates sales of more than $1.3 billion.

Dr Jens Riesle - Chief Scientific Officer and Executive Director

Jens Riesle obtained his PhD in Biochemistry from the University of Munich and the Max-Planck-Institute of Biochemistry in Germany and published in leading scientific journals including Nature. He also holds a postgraduate degree in business administration from the University of Hagen in Germany. After joining the Massachusetts Institute of Technology as a visiting scientist in cartilage tissue engineering in 1996, he started and build IsoTis’s cartilage repair program from 1998 as a Senior Research Scientist and R&D Manager to a clinical level.

Dr Jeanine Hendriks - Product Development Manager

Jeanine Hendriks obtained her PhD degree at the University of Twente on the influence of cellular inaction in tissue engineering of cartilage tissue, which provided the basis for the interoperative cell therapy CellCoTec is currently developing. From 1993 she held several positions as a researcher at the University of Wageningen and Hubrecht Laboratory (Dutch institute for Developmental Biology) before joining IsoTis in 1999. As a Manager Cartilage Product Development, she was responsible for product development, transfer to production and the successful launch of IsoTis’ first generation cartilage product.

Brian Steer - Non-executive Chairman of the Board of Directors

is among the best-known leaders in the global medical device industry. He is currently the Chairman of Gyrus plc, UK’s second largest publicly traded medical device company and part of the FTSE 250 index. Gyrus currently has a market capitalization of nearly $1.2 billion (October 2007) and sales of nearly $500 million. He joined Gyrus in 1997 as Executive Chairman and shortly thereafter, the company was listed on the London Stock Exchange. Under his leadership, the company has progressed from a company making products for others into a global leader in its field of tissue management and visualization during surgical procedures. As part of this process, he has led and completed numerous acquisitions to build Gyrus. His experience spans forty-five years of management within the healthcare industry, including twenty years with Baxter Healthcare, which he joined in 1963, holding several positions within the International Division, including President of Europe. He spent a further 10 years as President of Zimmer International, a world leading orthopedic company ($19 billion market cap) and at the time, a division of Bristol Myers Squibb. In 1993, he formed Steer Associates, consulting for Orthofix, Gyrus, Genetics Institute, and others. He later became Director and Chief Operating Officer of Orthofix. In 1995, he led a buy-in/buy-out of Cremascoli, an Italian orthopaedic company, subsequently sold to Warburg Pincus, before joining Gyrus full-time.

Dr Jaap Kampinga - Non-executive Director

began his professional career as a medical doctor and academic scientist in 1984 after obtaining a medical degree from the University of Groningen. He is a named author on over 35 scientific publications. In 1994, he became the R&D director of Quadrant Healthcare plc. Quadrant floated on the London Stock Exchange in 1998 and was sold to Elan Pharmaceuticals in 2000. Dr. Kampinga was an executive director and a key member of the team that promoted the initial public offering. In 2000, he became co-founder and CEO of the Dutch inflammatory disease company JARI Pharmaceuticals BV, and thereafter he became CEO of the Dutch photodynamic therapy company PhotoBioChem NV. In 2003, he became a managing director of Oakes, Lyman & Co. Limited, a firm specializing in structuring, building, and financing medical businesses, and the investment advisor of the OLK Medical Fund.

Professor Clemens van Blitterswijk - Non-executive Director

Professor van Blitterswijk is a Professor of Biocompatibility at Twente University, the Netherlands. During his career has co-founded four biomedical companies. He acted as CEO of IsoTis NV from 1996 to 2002. In total he raised over 120 Million Euros in funding through equity and/or grants. Resulting from his work 10 implant technologies were brought into clinical evaluation in humans.